Claims

ISS used to assess performance and identify risks: eighteen studies, mostly observational, reported positive benefits for identifying hazards, latent safety threats and guideline non-adherence

Claim · All claims
Evidence · 1 study · review r3 · q2
Currency · newest study 2022 · not yet checked against its sources · not reviewed by a person

Subclaims

Reading the evidence codes

q is the design tier, i the impact, n the sample, and the kind with its r the rigour judged within that kind: what each code means.

This claim: no standardized effect is recorded in observations/ for it yet, so no benchmark reading is possible.

q2 i? Eighteen studies used ISS as an assessment method to identify medication errors, latent safety threats, guideline non-adherence and equipment issues, and authors reported positive benefits for detecting errors and informing improvement initiatives. → Evans Kerry 2022

Evidence

Evans Kerry 2022

Evans Kerry, Woodruff Jenny, Cowley Alison, Bramley Louise, Miles Giulia, Ross Alastair, Cooper Joanne, Baxendale Bryn. (2022). GENESISS 2—Generating Standards for In-Situ Simulation project: a systematic mapping review. BMC Medical Education. https://doi.org/10.1186/s12909-022-03401-y

q2 · i? · review · r3

Review category 1: eighteen studies (samples where reported ranging from 12 to 277 participants) conducted ISS to assess performance and identify risks such as medication errors and latent safety threats. The review reports "Authors reported positive benefits of conducting ISS to identify risks and hazards in clinical environments".

"Eighteen studies conducted ISS as a method of assessment (Table 2). Studies were conducted in the US, Canada, Denmark, Sweden, UK, Germany, Switzerland. Most studies were observational (n = 17), with one study reporting a quasi-experimental design"

Discussion

Page metadata
Field Value
status review
generated by process:wiki-ingest on 2026-10-31
trust unverified — no one has confirmed this page's content

Frontmatter is the page's machine-readable record — see the Schema & Guide.